Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.

Sorry, there's nothing here.

Cite this paper

@article{Hugosson2001TumorVI, title={Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers.}, author={Jonas Hugosson and Hans Lilja and Per Lodding and Carl Gustaf Pihl}, journal={European urology}, year={2001}, volume={39 Suppl 4}, pages={33-4} }